Eli Lilly and Company
Rapid-acting insulin compositions

Last updated:

Abstract:

The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.

Status:
Grant
Type:

Utility

Filling date:

11 Jan 2018

Issue date:

23 Feb 2021